VIDEO: Alternating gemcitabine and gemcitabine/nab-paclitaxel may mitigate toxicity
In this video, Laleh Melstrom, MD, MS, discusses results from phase 2 ALPACA study presented at ASCO Gastrointestinal Cancers Symposium.
The study evaluated a dose-reduction regimen comparing standard treatment with gemcitabine/nab-paclitaxel with alternating gemcitabine/nab-paclitaxel and gemcitabine monotherapy in patients with metastatic pancreatic cancer.
"What it showed was that we could deescalate and do this alternating therapy where patients have less toxicity," Melstrom, a surgical oncologist at City of Hope, said.
Median overall survival in alternating treatment arm was 10.5 months, which was similar to the standard treatment arm, which was 10.4 months, Melstrom noted.
Reference:
- Dorman K, et al. Abstract 605. Presented at: ASCO Gastrointestinal Cancers Symposium; Jan. 18-20, 2024; San Francisco.
Collapse
Healio Interviews
Read more about